More than 10-fold enhanced viral vaccine production titers using the novel Cellevat3d® nanofiber microcarriers
LUND, Sweden, August 19, 2025 – Cellevate AB publishes today results from their vaccine production validation program that is designed to evaluate and validate the performance of the cell culture products based on proprietary nanotechnology Cellevat3d®.
In internal studies, the data demonstrated that Vero cells cultured on Cellevat3d® nanofiber microcarriers rapidly formed dense and uniform 3D spheroids, reaching high, viable cell densities. Importantly, the nanofiber-based microcarrier cell cultures successfully produced high infectious titers of enterovirus A71 (EV71).
In parallel, Intravacc B.V., a leading European CDMO specializing in vaccine manufacturing, conducted an independent benchmarking study using HEK 293T cells. The study compared Cellevat3d® nanofiber microcarriers with industry-standard microcarriers in enterovirus production. The outcome was compelling: a 11.4-fold increase in infectious virus titers and a 17-fold improvement in cell-specific virus yield using the nanofiber-based 3D cultures. These findings further validate the platform’s performance across diverse cell systems and production models.
“We are thrilled by these results, first and foremost because vaccine development and production are challenged by cost and time. By implementing Cellevat3d® nanofiber products, the cost of vaccine production could be reduced up to 85% compared to current traditional processes. The cost reduction is based on exceptional yield improvements, process simplicity, robust scalability, faster bioprocessing, reduced waste and water use, and improved process sustainability, all values provided by Cellevat3d® nanofiber products,” said Laura Chirica, CEO of Cellevate.
“Secondly, the flexibility of Cellevat3d® nanotechnology allows us to develop and commercialize new products for critical applications in advanced therapies production. Next in line is the Cellevat3d® VAX nanofiber product for vaccine production, to be launched at World Vaccine Congress in October 2025 in Amsterdam.”
A full summary of the performance data is available in a new Application Note at www.cellevate.com.
For more information, please contact:
Laura Chirica, PhD
CEO Cellevate
Email: laura.chirica@cellevate.com
About Cellevate
Cellevate is a Swedish biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture solutions for cell- and gene therapy and novel vaccines biomanufacturing. The core nanotechnology, Cellevat3d® is a sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of a new category of nanofiber cell culture systems – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to increased yield, productivity and process economy. Cellevat3d® nanofiber-based products are designed and validated as an integrated part of upstream bioprocessing solutions, from laboratory to large-scale production.
For more information, please visit www.cellevate.com.
About Intravacc
Intravacc, located at Utrecht Science Park Bilthoven in the Netherlands, is a leading global contract development and manufacturing organization (CDMO) of innovative vaccines against infectious diseases. As an established independent CDMO with an outstanding track record in vaccine development and vaccine technologies, Intravacc has transferred its technology related to polio vaccines, measles vaccines, DPT vaccines, Hib vaccines and influenza vaccines around the world. Around 40% of childhood disease vaccines are based on Intravacc’s proprietary technology. Intravacc offers a wide range of expertise to develop vaccine from concept to Phase I/II clinical studies for partners around the world, including universities, public health organizations (WHO, Bill & Melinda Gates Foundation), biotech and pharmaceutical companies.
For more information, please visit Intravacc B.V..